Dramatically improving survival and support for upper gastrointestinal cancers
We are the leading organisation inspiring hope, raising awareness, supporting families and funding research for upper gastrointestinal (GI) cancers. With one of the lowest survival rates out of all the major cancers, it’s our mission to improve survival and support for Australians diagnosed with pancreatic, liver, stomach, biliary and oesophageal cancers – from the point of diagnosis to treatment and beyond.
How can we help?
A cancer diagnosis can come as a terrible shock, but we’re here to help you every step of the way. Learn more about how to manage living with pancreatic, liver, stomach, biliary or oesophageal cancer.
Meet others living with upper GI cancers in a supportive environment. Our PanSupport groups discuss a range of topics, including symptom management, treatments and emotional wellbeing.
Our friendly team are dedicated specialists in upper gastrointestinal (GI) cancer care and are available to support you and your family in a variety of ways on your cancer journey.
ARTICLES, NEWS & EVENTS
The Pharmaceutical Benefits Scheme (PBS), delivered welcomed news for Australians living with biliary cancer this week with IMFINZI® (durvalumab) being made available for patients diagnosed with advanced or metastatic biliary tract cancer (BTC) from 1 December 2023.
Patients will now have reimbursed access to IMFINZI® (durvalumab) – the first new treatment in over ten years for this incurable disease. This will mean the cost of treatment is significantly reduced - helping patients have equitable access to treatments.
November is Pancreatic Awareness Month.
This globally recognised initiative is our community's time to raise awareness for Pancreatic Cancer, to advocate for increased funding, celebrate survivors, and remember the loved ones we have lost.
Because most people have few if any, detectable symptoms in the early stages, this aggressive cancer is typically diagnosed at later, more advanced stages.
PBAC recommends subsidised therapies for biliary and oesophageal cancers
The Pharmaceutical Benefits Advisory Committee (PBAC) last week announced two positive recommendations for therapies that will benefit biliary and oesophageal cancer patients. The therapies brought to PBAC have been submitted by two different companies, who made recommendations to have the medications listed on the Pharmaceutical Benefits Scheme (PBS), enabling patients to have greater access to more affordable treatments.